Mattes Glenn R. 4
4 · TFF Pharmaceuticals, Inc. · Filed Nov 13, 2020
Insider Transaction Report
Form 4
Mattes Glenn R.
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2020-11-10$14.99/sh−108,830$1,631,906→ 10,000 total - Exercise/Conversion
Stock Options (Right to Buy)
2020-11-10−108,830→ 1,104,227 totalExercise: $2.50From: 2019-05-01Exp: 2028-05-01→ Common Stock (108,830 underlying) - Exercise/Conversion
Common Stock
2020-11-10$2.50/sh+108,830$272,075→ 118,830 total
Holdings
- 10,000(indirect: By Spouse)
Common Stock
Footnotes (1)
- [F1]The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.